Breakthrough Blood Cancer Therapy Looms as Medicare Weighs Costs

August 28, 2019

A breakthrough treatment for the third most common blood cancer could be the next novel CAR T-cell therapy to gain Food and Drug Administration (FDA) approval as Medicare weighs its ability to fund the growing field of costly therapies.